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HLAHCV infection transmission rate in infants born to HCV-positive mothers is about 5%. HIV co-infection and
high maternal RNA viral load are associated with increased transmission. The only genetic factor previously
evaluated is HLA. We investigated the role of genetic factors already associated in adults with HCV infection
evolution (HLA-DRB1, MBL2, TNF-α, IFN-γ and IL-10), or liver disease progression (HFE and TGF-β1). 384
Italian subjects were recruited, including 38 HCV-positive mother/child pairs; 104 infected, non-transmitting
mothers with their 114 children; 21 vertically infected children and 69 HCV-exposed, uninfected children.
Samples were analysed for previously described gene polymorphisms. Maternal HLA-DRB1⁎04 correlated
with protection from vertical transmission (p=0.023), while HLA-DRB1⁎10 in children was a risk factor
(p=0.036). Investigation of concordance degree in HLA-DRB1 locus revealed that a HLA mismatch between
mother and child was a protective factor (p=0.017) indicating that alloreactive immune responses are
involved in preventing HCV vertical transmission.© 2009 Elsevier Inc. All rights reserved.IntroductionThe rate of mother-to-child (vertical) transmission of hepatitis C
virus (HCV) is about 5%, with the highest risk in women with HIV co-
infection (EPHN, 2005; Pembrey et al., 2005; Zanetti et al., 1999).
Among other possible risk factors, the only one consistently found to
be associated with transmission was maternal plasma RNA viral load,
though a speciﬁc cut-off value predicting or excluding transmission
has been not deﬁned (EPHN, 2005; Resti et al., 1998). The importance
of mode of delivery (vaginally or by caesarean section) and type of
feeding (breastfeeding or replacement feeding) have been investi-
gated for their possible inﬂuence on transmission, but no signiﬁcant
effects have been noted in most studies (EPHN, 2005; Mast et al.,
2005; Pembrey et al., 2005; Resti et al., 1998; Zanetti et al., 1999).so)
Servizio Immunotrasfusionale,
Trieste”, Strada di Fiume 447,
ll rights reserved.The relevance of the genetic background has also been taken into
consideration. Several candidate genes, most of them involved in
natural and acquired immunity, have been evaluated in adults ex-
posed to HCV infection or suffering of related chronic liver diseases.
Predisposing alleles to HCV infection may be implicated also in ver-
tical transmission, as well as genes relevant for liver disease prog-
ression. Attention has been mainly focused on the Human Leucocyte
Antigen (HLA) system, because of its central role in adaptive res-
ponses. Concerning vertical transmission, in one study (Bosi et al.,
2002) a signiﬁcant negative association between children's HLA-
DR13 antigen and risk of HCV infection was noted. In another study
(Martinetti et al., 2006) HLA-DRB1⁎0701 and -DRB1⁎1401 alleles in
the child had a predisposing role for transmission, while HLA-
DRB1⁎1104 and -DRB1⁎1302 alleles were apparently protective. In the
present study we investigated the implication for HCV vertical trans-
mission of some genetic factors, mainly involved in the host immune
response, which modulate the susceptibility to chronic HCV infection
(HLA-DRB1,MBL2, coding for Mannose Binding Lectin protein –MBL –,
TNF-α, IFN-γ and IL-10, coding respectively for Tumor Necrosis
Factorα, Interferon γ and Interleukin 10 cytokines), and the severity of
Table 1
Relative frequencies of different HCV genotypes in transmitting and non-transmitting
mothers.
HCV
genotype
Mothers of HCV+
children N (%)
Mothers of HCV−
children N (%)
P
1 14 (0.42) 12 (0.54) NS
2 3 (0.10) 8 (0.36) 0.034
3 12 (0.36) 2 (0.10) 0.023
4 4 (0.12) 0 (0.0) NS
Total 33 22
NS: not signiﬁcant.
Table 3
Degree of HLA-DRB1 mismatch between mother and child according to HCV vertical
transmission.
Couples Number HLA-DRB1 mismatch
1 0
HCV+ mother, HCV− child 48 41 (85%) 7 (15%)
HCV+ mother, HCV+ child 38 24 (63%) 14 (37%)
Total 86 65 (76%) 21 (24%)
Note: no more than 1 mismatch is expected between mother and child. When HLA-
DRB1 typing of the mother was homozygous, or when she carried the same HLA-DRB1
alleles of the child, then maternal cells have no mismatch with the child.
⁎p=0.017; OR 3.42; 95% CI=1.09–11.34.
65E. Bevilacqua et al. / Virology 390 (2009) 64–70liver disease in infected adults (HFE, coding for HFE, a protein involved
in ironmetabolism, and TGF-β, coding for Transforming Growth Factor
β cytokine) (Barrett et al., 2003; Dai et al., 2006; Segat et al., 2007;
reviewed in de Andrade Júnior and de Andrade, 2004).
Results
HCV genotype
Data on viral genotype were available for 33 transmitting and 22
non-transmitting mothers. In order to compare transmitting and non-
transmitting mothers, due to the small number of samples genotyped
for HCV virus, and because there were no data available on viral
subtype for many patients, we grouped together all samples with
the same viral type and we didn't consider viral subtypes. Compa-
rison between transmitting and non-transmitting mothers (Table 1)
showed that HCV genotype 2 was signiﬁcantly more frequent in
non-transmitting mothers (p=0.034; OR 0.18; 95% CI=0.027–0.90),
while HCV genotype 3 was more frequent in transmitting mothers
(p=0.023; OR 5.5; 95% CI=1.04–57.3).
HLA typing
HLA typing was performed in 48 pairs of HCV+ mother/HCV−
child and in 38 couples of HCV+ mother/HCV+ child. Their HLA-
DRB1 frequencies were not different from those of the Italian pop-
ulation (data not shown, Amoroso et al., 1998).
Maternal and children's relative frequencies of the HLA-DRB1
alleles are reported in Table 2. Comparison between transmitting and
non-transmitting mothers showed that the HLA-DRB1⁎04 allele was
signiﬁcantly more frequent in non-transmitting women (p=0.023;
OR 0.187; 95% CI=0.0192–0.962).
Fromthe comparisonof allelic frequencies betweenHCV+andHCV−
children, the HLA-DRB1⁎10 allele was signiﬁcantly more frequent in
infected than uninfected children (p=0.036; OR not determinable).Table 2
Relative frequencies of the different HLA-DRB1⁎ alleles in infected and uninfected children
Allele DRB1⁎ Mothers
Non-transmitters
(N=48)
Transmitters
(N=38)
N (%) N (%)
⁎01 7 (0.0729) 5 (0.0658)
⁎03 7 (0.0729) 10 (0.1316)
⁎04 11 (0.1146) 2 (0.0263)
⁎07 11 (0.1146) 12 (0.1579)
⁎08 5 (0.0521) 1 (0.0132)
⁎09 2 (0.0208) 2 (0.0263)
⁎10 0 (0.0000) 3 (0.0395)
⁎11 20 (0.2083) 11 (0.1447)
⁎12 0 (0.0000) 1 (0.0132)
⁎13 14 (0.1458) 12 (0.1579)
⁎14 7 (0.07299 7 (0.0921)
⁎15 6 (0.0625) 7 (0.0921)
⁎16 6 (0.0625) 3 (0.0395)
Total 96 (100) 76 (100)Mother and child share at least one HLA-DRB1 allele. We assigned
mismatch value 0 when the mother was homozygous or she was
heterozygous for the same HLA alleles also present in her child (i.e.
mother's cells would not be recognized as foreign). The HLA-DRB1
concordance degree differed signiﬁcantly between transmitting and
non-transmittingmothers (p=0.017) (Table 3). The transmission rate
was signiﬁcantly higher in mother–child pairs without any HLA-DRB1
mismatch (p=0.017; OR 3.42; 95% CI=1.09–11.34).
MBL2 gene sequencing
Since R52C, G54D and G57E polymorphisms have the same effect
of reducing the levels of functional circulating MBL protein, we
grouped all these allelic variants as “0 allele”, while with “A allele”we
referred to the wild type alleles at the same codons.
We performed direct sequencing of MBL2 exon 1 for detecting
R52C, G54D and G57E polymorphisms in 30 HCV+ couples mother/
child, 18 HCV+ children, 49 couples HCV+ mother/HCV− child and
56 HCV− children.
Allelic frequencies of the 0 allele were 0.17 in HCV+ children, 0.162
in HCV− children, 0.166 in mothers of HCV+ children and 0.22 in
mothers of HCV− children. Comparing infected vs. uninfected
children or transmitting vs. non-transmitting mothers, no signiﬁcant
differences were found in the frequencies of 0 allele.
The allelic and genotypic frequencies of these cohorts of subjects
were not different from those of 164 healthy controls (data not shown,
Segat et al., 2008).
Cytokine gene polymorphisms
We selected cytokine gene polymorphisms which affect the ex-
pression levels of the produced protein (Awad et al., 1998; Dai et al.,
2006; Kroeger et al., 1997; Turner et al., 1997; Wilson et al., 1997).and in their mothers.
Exposed children
P Uninfected
(N=48)
Infected
(N=38)
P
N (%) N (%)
0.855 11 (0.1146) 4 (0.0526) 0.152
0.2 6 (0.0625) 8 (0.1053) 0.308
0.023 10 (0.1042) 4 (0.0526) 0.21
0.407 10 (0.1042) 8 (0.1053) 0.974
0.335 7 (0.0729) 4 (0.0526) 0.82
0.785 1 (0.0104) 2 (0.0263) 0.837
0.084 0 (0.0000) 4 (0.0526) 0.0364
0.281 20 (0.2083) 11 (0.1447) 0.281
0.441 1 (0.0104) 1 (0.0132) 1
0.797 14 (0.1458) 13 (0.1711) 0.65
0.647 8 (0.0833) 6 (0.0789) 0.916
0.465 4 (0.0417) 6 (0.0789) 0.34
0.742 4 (0.0417) 5 (0.0658) 0.51
96 (100) 76 (100)
66 E. Bevilacqua et al. / Virology 390 (2009) 64–70Table 4 details the number of subjects and the relationship with the
expression level for each polymorphism.
We grouped together intermediate and low cytokine producers,
and compared them with high cytokine producers. No signiﬁcant
differences were observed between infected and uninfected children
or between transmitting and non-transmitting women. Nor did they
differ for allelic or genotypic frequencies in respect to a control popu-
lation of 51 healthy subjects (data not shown, unpublished results).
HFE analysis
The H63D mutation in the HFE gene was investigated in 38 trans-
mitting and 51 non-transmitting women. Allelic frequencies of the
63D allele were 0.118 in the former and 0.144 in the latter (p=0.61).
These frequencies are not signiﬁcantly different from the Italian pop-
ulation (data not shown, Candore et al., 2002).
Discussion
We assessed the possible role of viral genotype and of selected
candidate genetic factors for HCV vertical transmission. We mostly
took into consideration genes involved in the host immune response,
whose effects in the susceptibility to chronic HCV infection or in liver
disease progression have been assessed (Dai et al., 2006; Erhardt
et al., 2003; Hue et al., 2002; Koutsounaki et al., 2008; Mangia et al.,
2004; Powell et al., 2000; Segat et al., 2007; Yenigun and Durupinar,
2002).
Viral genotype
Few studies investigated the role of HCV genotype as a risk factor
for HCV vertical transmission. In our study, correlation between
mothers' HCV genotype and vertical transmission revealed that
genotype 3 is a risk factor, while genotype 2 is less involved in the
transmission of HCV infection. Interestingly, HCV genotype 3 has been
reported as a risk factor for vertical transmission also by Zuccotti et al.
(1995). In contrast to previous works (Mok et al., 2005; Zuccotti et al.,
1995), we did not ﬁnd a difference in genotype 1 prevalence between
transmitting and non-transmitting mothers.
Moreover, our data indicate that HCV genotype 2 correlates with a
lower risk of vertical infection. To our knowledge this is the ﬁrst report
describing such correlation.
Though statistical differences were seen, we feel that the number
of cases is too small for any ﬁrm conclusions.Table 4
Frequencies of polymorphisms of some cytokine genes – grouped according to their relevan
Gene and
polymorphisms
Genotype Phenotyp
TNF-α A/A or G/A High
−308 G/G Low
Total
IL-10 GCC/GCC High
−1082, −819, −592 GCC/ACC or GCC/ATA Intermed
ACC/ACC or ACC/ATA or ATA/ATA Low
Total
IFN-γ T/T High
+874 T/A Intermed
A/A Low
Total
TGF-β1
Codons 10 and 25 T/T G/G or T/C G/G High
T/C G/C or C/C G/G or T/T G/C Intermed
C/C G/C or C/C C/C or T/T C/C or T/C C/C Low
TotalHLA-DRB1
Several studies in adults have reported a strong association of
certain HLA-DRB1 alleles with clearance (Barrett et al., 1999; Yenigun
and Durupinar, 2002) or persistence of HCV infection (Hue et al.,
2002; Thio et al., 2001). However, to date the role of the HLA reper-
toire in HCV vertical transmission has only been investigated in two
studies, with discordant results: Bosi et al. (2002) found a protective
role of HLA-DR13 antigen in exposed children, while Martinetti et al.
(2006) found that the HLA-DRB1⁎0701 and DRB1⁎1401 alleles are
associated with an increased risk of transmission, and HLA-DRB1⁎1104
and DRB1⁎1302 alleles seemingly protect from the infection. Our
ﬁndings do not conﬁrm any of these previous ﬁndings, which might
be due to the fact that the two previous studies analysed a limited
cohort of patients, increasing possible statistical errors. In fact, Bosi et
al. analysed 18 HCV+ children with 8 of their mothers and 17 HCV−
childrenwith 12 of their mothers; Martinetti et al. analysed 21 couples
HCV+ mother/HCV+ child and 44 couples HCV+ mother/HCV−
child. Furthermore, in our study, samples were collected from diffe-
rent Italian regions, whereas the geographic origin of the previous
populations was homogenous, so it is possible that relative analyses
had been inﬂuenced by a particular genetic background (Amoroso
et al., 1998).
In our study, HLA-DRB1⁎04 was signiﬁcantly more frequent in
non-transmitting mothers than in transmitters, suggesting a possible
protective effect of this allele. This might be explained by a greater
ability of subjects carrying HLA-DRB1⁎04 allele in presenting HCV
epitopes to T cells than subjects carrying other HLA-DRB1 alleles.
This hypothesis is in line with the study of Diepolder et al. (1997)
who showed that speciﬁc HLA-DR antigens (i.e. DR4, DR11, DR12,
DR13, DR16) are particularly able to present speciﬁc HCV epitopes to
T lymphocytes, with consequent viral clearance. If so, mothers
carrying HLA-DRB1⁎04 might have a lower plasma HCV RNA viral
load, and could thus be at lower risk of transmitting the virus to
their offspring. Unfortunately, we cannot verify this hypothesis
because viral load during pregnancy was not available for most
women in this study. It is worth noting that in an Irish adult female
population, the HLA-DRB1⁎0401 allele was associated with HCV
clearance (McKiernan et al., 2004). Similarly, Cramp et al. (1998)
demonstrated that the DRB1⁎04-DQA1⁎03-DQB1⁎0301 haplotype
was related to spontaneous clearance of HCV infection and suggested
that the primary association was likely with DQB1⁎0301 while the
associations with DRB1⁎04 and DQA1⁎03 were due to linkage
disequilibrium.ce on expression levels – in both infected and uninfected children and in their mothers.
e Mothers N (%) Children N (%)
HCV− children HCV+ children HCV− HCV+
12 (32) 3 (14) 9 (24) 7 (21)
26 (68) 19 (86) 29 (76) 26 (79)
38 (100) 22 (100) 38 (100) 33 (100)
4 (11) 6 (27) 4 (11) 7 (21)
iate 19 (53) 12 (55) 21 (55) 15 (46)
13 (36) 4 (18) 13 (34) 11 (33)
36 (100) 22 (100) 38 (100) 33 (100)
9 (32) 4 (18) 6 (18) 8 (24)
iate 11 (39) 12 (55) 21 (64) 15 (46)
8 (29) 6 (27) 6 (18) 10 (30)
28 (100) 22 (100) 33 (100) 33 (100)
12 (52) 11 (65) 17 (63) 14 (56)
iate 9 (39) 5 (29) 9 (33) 9 (36)
2 (9) 1 (6) 1 (4) 2 (8)
23 (100) 17 (100) 27 (100) 25 (100)
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carrying the HLA-DRB1⁎10 allele. The HLA-DRB1⁎1001 allele has been
associated with viral persistence and chronic liver disease in an Italian
population (Asti et al., 1999). We did not perform high resolution
typing of HLA-DRB1 alleles, but, since the majority of DRB1⁎10 are
⁎1001, it is possible that also in our population the HLA-DRB1⁎10
allele impairs the HCV recognition and its clearance. This result is also
supported by the ﬁnding that maternal HLA-DRB1⁎10 shows the
tendency to be a risk factor for vertical transmission, although at the
limit of signiﬁcance (p=0.084).
More interesting, from the HLA study, it emerged that a HLA
mismatch between mother and child, in the direction of the mother,
was protective for transmission (p=0.017). In fetuses and in new-
borns in fact, an allogenic anti-maternal immune response might
result in some degree of protection against HCV infection, and this
response can occur only if some difference in MHC molecules does
exist. In line with this hypothesis is the evidence that HCV infection of
maternal Peripheral Blood Mononuclear Cells (PBMCs) is associated
with vertical transmission (Azzari et al., 2000, 2008). Moreover, the
authors (Azzari et al., 2000) found that the presence in PBMCs of
active HCV replication was associated with a greater risk of vertical
transmission. Even though the possibility that HCV infects lymphoid
cells is not deﬁnitively assessed, there are many experimental data
in line with this hypothesis (reviewed by Zignego et al., 2007). More-
over, prolonged survival of maternal cells in the offspring has been
observed when they are HLA-identical (Billington, 1992). This me-
chanism of protection may represent a general strategy for the off-
spring to be protected from a variety of intracellular pathogens, even
when they infect cells different from PBMCs, and also explains the
wide HLA diversity among populations.
Another possible explanation of increased risk on HCV vertical
transmission for HLA-DR matched pairs involves the selective pres-
sure exerted by maternal immune response against the virus. In this
situation, HCV variants that are able to escape maternal immune
response can emerge and be transmitted to the offspring. Conse-
quently childrenwho are HLA-concordant to their mother might be at
greater risk of infection because they could receive viral variants
selected to escape their own immune response. In fact HCV exhibits
considerable genetic diversity, and closely related “quasi species” are
found circulating within individuals (Martell et al., 1992). Quasi
species emerge under the selective pressure of the host immunity,
such as a HLA-restricted T-cell response (Diepolder et al., 1997).
In the group of zero HLA-DR mismatches between mother and
child, we also included pairs with HLA-DR homozygous mothers,
against whom no HLA-DR incompatibilities were seen by the immune
system of the child. In some chronic virus infections, including HCV
(Hraber et al., 2007), HBV (Thursz et al., 1997) and HIV (Mackelprang
et al., 2008), a heterozygote advantage has been reported. In parti-
cular, Hraber et al. (2007) found that the heterozygous advantage, in
HCV-infected subjects, involved onlyHLA-DRB1 locus.We can suppose
that, in our study population, homozygous mothers may have a higher
viral load and a worse disease status due to a diminished repertoire of
epitope presentation to T cells, so contributing to the concordance-
related risk of vertical infection. However, in our study population,
HLA homozygosity alone is not involved in the risk of HCV vertical
transmission, possibly due to the small number of subjects analysed
(data not shown).
Indeed in another study (Azzari et al., 2007) there was no signi-
ﬁcant difference in the HLA class I concordance between transmitting
and non-transmittingmothers. These apparently contradictory results
might be accounted for by the different roles that HLA-Class I and
Class II antigens play in the immune response and in allorecognition.
In fact, during the alloreactive immune response, foreign HLA class I
antigens are recognized by CD8+ T lymphocytes that subsequently
lyse the cell. On the other hand, HLA class IImolecules are recognized by
CD4+ T lymphocytes that are activated and produce cytokines. Inaddition to antigen recogniton, T cell activation requires the contem-
porary presence of costimulatory signals by specialized Antigen-
Presenting Cells (APCs), as like PBMCs. Antigen recognition in the
absence of costimulatory factors may have a tolerogenic effect
(mechanisms of allorecognition are reviewed byWhitelegg and Barber,
2004). In this contest, the HLA discordance at class II level could play an
important role, together with the HLA class I allorecognition. Moreover
Azzari et al. (2007) employed a serologicmethod to deﬁneHLA antigens
that leads to a lower resolution level with respect to molecular
techniques to asses mother-to-child HLA concordance values.
Other genes
MBL (Mannose Binding Lectin) is a protein capable to bind to a
wide range of microorganisms, interacting with sugars on their sur-
face, and is thereby able to activate the complement system and
phagocytosis. MBL can also promote opsonophagocytosis, interacting
directly with cell surface receptors, by a complement independent
pathway (Turner et al., 1997). For these properties, MBL provides the
host with a ﬁrst line of defence against sugar decorated pathogens and
in humansmay be particularly important in infants when the adaptive
response is still immature (Summerﬁeld et al., 1995). LowMBL serum
levels are associated with an increased risk of several infections in
adults and children (Sumiya et al., 1991; Summerﬁeld et al., 1995).
MBL deﬁciency is largely explained by three single nucleotide poly-
morphisms in the ﬁrst exon of MBL2 gene, R52C, G54D and G57E
(Turner, 1996); these polymorphisms do not allow MBL subunits to
reach the correct basic trimeric structure, andmake the subunits more
vulnerable to degradation, or both, thus reducing the amount
of functional MBL subunits in heterozygous individuals by 5 to 10
folds. A few number of studies have investigated the role of MBL2
polymorphisms in susceptibility to HCV infection and in disease
progression: Segat et al. (2007) showed an increased frequency of the
MBL2 0 allele in HCV-infected patients as compared to healthy
controls in a Brazilian population. Koutsounaki et al. (2008) found
that polymorphism homozygosity in the ﬁrst exon of MBL2 gene was
related to progression of HCV infection to liver inﬂammation and
ﬁbrosis in a group of 80 Caucasian HCV-infected patients.
Cytokines are further important factors in the regulation of the
immune system. A few studies have evaluated the role of cytokine
polymorphisms in the outcome of HCV infection in adults (Barrett et
al., 2003; Dai et al., et al., 2006; Höhler et al., 1998; Powell et al., 2000).
TNF-α is a pro-inﬂammatory cytokinewhich is increased inpatients
with acute and chronic hepatitis C and the virus infection induces
TNF-α production in human hepatocytes. The G to A transition at
position −308 in the TNF-α promoter region inﬂuences the TNF-α
expression. This polymorphism is associated with higher constitutive
and inducible levels of TNF-α (Wilson et al., 1994) and correlates with
severe hepaticﬁbrosis inpatientswith chronic liver disease (Jeng et al.,
2007). Conversely, no signiﬁcant differences in the frequency of this
polymorphism emerged between patients with active chronic hepa-
titis C and healthy controls in Caucasians (Höhler et al., 1998).
IFN-γ is a cytokine produced by activated Tcells and NK cells with a
wide variety of antiviral, antiproliferative and immunomodulatory
effects. An adequate Th-1 response, with consequent high IFN-γ sec-
retion, is associated with a protective antiviral response (Koziel et al.,
1995), while insufﬁcient systemic Th1 secretion is related to increased
viral load and disease progression (Koziel et al., 1995; Lechmann et al.,
1999). In the ﬁrst intron of the gene, the +874 T to A polymorphism
affects the expression levels of the protein: the presence of the poly-
morphism decreases the amount of cytokine produced to an inter-
mediate (T/A genotype) or low (A/A genotype) level. The +874 T to
A polymorphism is associated with cirrhosis in HCV patients (Dai
et al., 2006) and with early HCV recurrence in those who underwent
orthotopic liver transplantation for HCV-related liver disease (Ben-Ari
et al., 2004).
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kines, such as IL-10. In the promoter region of the IL-10 gene there are
three polymorphisms,−1082 (G to A),−819 (C to T) and−592 (A to
C), which inﬂuence cytokine secretion. The combination of these
polymorphisms results in three different haplotypes (GCC, ACC and
ATA) corresponding to three different phenotypes (high, intermediate
or low producers of IL-10, respectively) (Barrett et al., 2003). Self-
limiting HCV infection is associated with the ATA lower cytokine
producing genotype (Mangia et al., 2004) or to IL-10 (−592) AA
genotype (Knapp et al., 2003), while persistent HCV infection is
associated with the IL-10 (−1082) GG genotype (Knapp et al., 2003).
TGF-β gene encodes an anti-inﬂammatory cytokine that promotes
ﬁbrinogenesis and favors hepatic ﬁbrosis in chronic HCV infection.
Two polymorphisms have been described in the leader sequence of
TGF-β gene, 29CNT (Leu10Pro) and the 74CNG (Arg25Pro): the ﬁrst
reduces the export efﬁciency of the newly synthesized protein, while
the second polymorphism leads to decreased production of TGF-β
(Grainger et al., 1999). There is a signiﬁcant association between the
TGF-β C/C G/C genotypes and viral clearance in infected subjects,
suggesting that the low-producing phenotype may protect against
persistent infection (Barrett et al., 2003).
The hemochromatosis type I gene (HFE) codes for a protein involved
in ironmetabolism. Mutations in this gene correlate with an increased
iron absorption and deposition in parenchymal organs leading to
multiorgan failure. In liver, iron overload may promote HCV replica-
tion, increase oxidative stress and impair host immunity (Congia et al.,
1996). Two major mutations in HFE gene, Cys282Tyr and His63Asp,
are responsible for about 90% of the cases of type 1 hereditary hemo-
chromatosis in western populations. C282Y or H63D heterozygosity
are two independent risk factors for liver ﬁbrosis and cirrhosis in HCV-
infected individuals (Erhardt et al., 2003).
By comparing the allelic frequencies of the above mentioned poly-
morphisms between HCV-infected and uninfected children, as well as
between mothers of HCV+ children and those of HCV− children, no
statistically signiﬁcant differences were found. This suggests that
these polymorphisms do not play a major role in HCV vertical trans-
mission, although no deﬁnitive conclusion can be drawn, because the
limited number of analysed subjects is not sufﬁcient to reveal a weak
association between these genes and HCV transmission.
We are also aware that an important limitation of our study is the
lack of information concerning maternal viral load at the time of
delivery. We have been able to retrieve retrospectively the viral loads
for a very little number of samples, so it was not possible to perform
any statistical analysis.
It is known that high viral loads are associated with an increased
rate of vertical transmission, so it has to be considered that ourTable 5
Origin and composition of the study population.
Origin of samples Paviaa Novarab Trentoc Milanod Milan
HCV+ mother/HCV+ child couples 4 – – 6 1
HCV+ children – 1 5 1 1
HCV+ mother/HCV− child couples 22 2 – 15 20
HCV− children from HCV+ mothers 2 4 58 – –
HCV+ mother/two HCV− children 9 – – – 1
Total subjects 81 9 63 43 46
Children born from 1993 1994 1998 1987 2002
To 2003 2004 2004 2004 2004
a Dipartimento di Pediatria, IRCCS Policlinico San Matteo, Pavia.
b Clinica Pediatrica, Università del Piemonte Orientale, Novara.
c Divisione di Pediatria, Ospedale Santa Chiara, Trento.
d Ospedale San Paolo, Milano.
e Clinica Pediatrica, Università di Milano, Ospedale Sacco, Milano.
f Dipartimento di Pediatria, Università di Totino, Torino.
g Centro di Neonatologia, Ospedale Infantile Regina Margherita, Torino.
h Clinica Malattie Infettive, Università di Genova, Genova.
i Università di Bologna, Bologna.
j Dipartimento di Pediatria, Università Federico II, Napoli.ﬁndings could be biased by the absence of information about the viral
loads of the mothers.
Taken together our data, considering the limiting factor due to the
absence of the viral loads of the mothers, conﬁrm that the genetic
factors predisposing to vertical transmission differ, at least in part,
from those involved in disease progression and viral clearance. Fur-
ther studies involving different populations are necessary to conﬁrm
the role of HLA-DRB1⁎04 and HLA-DRB1⁎10 alleles in HCV vertical
transmission.
Materials and methods
Subjects
Cases
Three hundred and eighty four Italian subjects were recruited, as
follows:
• 38 mother/child pairs, both with HCV infection (HCV+)
• 94 infected mothers with their HCV-negative (HCV−) child
• 10 HCV+ mothers with two concordant HCV− children
• 21 HCV+ children for whom maternal samples were not available
• 69 exposed, HCV− children without the maternal samples.
In the case of mothers with two HCV-uninfected children, only the
older child was included in the genetic study. Data on samples origin
are summarized in Table 5.
All HCV seropositive women were identiﬁed at or before delivery,
and their children were prospectively followed up as described
elsewhere (EPHN, 2005; Pembrey et al., 2005). In particular, vertically
exposed children were taken to be HCV-infected when they had
positive PCR results in at least two separate determinations and/or
were seropositive beyond 18 months of age. Children who seror-
everted and had less than two positive PCR ﬁndings were taken to be
uninfected.
Unfortunately, for most samples, data on maternal plasma RNA
viral load and on viral genotype were not available. An informed
consentwas obtained for the collected samples in accordancewith the
local Ethical Committees guidelines.
Controls
Unrelated Italian healthy subjects, without HCV infection, matched
for regional origin, served as control population. Allelic and genotypic
frequencies were available for each genetic polymorphism analysed in
the present work, thanks to previous association studies already
performed in our laboratory: for each gene, the number of controls
used was different: 109 for HLA-DRB1 (Amoroso et al., 1998); 51 foroe Torinof Torinog Genovah Bolognai Napolij Total Total subjects
13 – 2 6 6 38 76
6 – 6 1 – 21 21
14 9 – 4 8 94 188
4 – 1 – – 69 69
– – – – – 10 30
64 18 11 21 28 384
1989 – 1985 – –
2004 – 1986 – –
69E. Bevilacqua et al. / Virology 390 (2009) 64–70TNF-α, IFN-γ, IL-10 and TGF-β1 (unpublished results); 164 for MBL2
(Segat et al., 2008) and 578 for HFE (Candore et al., 2002).
Sample collection and DNA extraction
Blood samples were taken from all subjects during routine medical
controls, and were collected on Isocode Guthrie cards (Schleicher &
Schuell BioScience, Germany), that lyse cells on contact, including
viruses and bacteria, but preserve DNA from degradation.
Genomic DNA extraction was performed according to the manu-
facturer's instructions, by a simple boil and go protocol.
Because of the poor yield of Guthrie cards DNA extraction, it was
not possible to perform all the scheduled analyses for all samples. For
each gene taken into consideration, the number of samples analysed
was reported in the relative Results section. Table 1s (Supplementary
material) details the origin and the number of samples analysed for
each polymorphism.
HCV detection and genotyping
Laboratory investigations were performed locally. HCV infection
was diagnosed by antibody tests and qualitative HCV RNA PCR with
standard methods. HCV genotypes were identiﬁed according to the
classiﬁcation of Simmonds et al. (1994).
HLA typing
HLA-DRB1 low-resolution typing was performed by the PCR-
sequence-speciﬁc-primer method, using the Dynal AllSet SSP DR
“Low Resolution” kit (Dynal Biotech A.S.A., Norway). PCR ampliﬁca-
tions were carried out in a Gene Amp PCR System 9700 thermal cycler
(Applied Biosystems). PCR mixtures were loaded in a 2% agarose gel,
and observed under UV illumination after ethidium bromide staining;
results were documented by photography.
The HLA-DRB1 which remained not resolved at low resolution
were analysed with the Olerup “High Resolution” kits (Roche Mole-
cular Systems, Alameda, California) in accordance with the manufac-
turer's instructions.
MBL2 gene sequencing
The MBL2 gene was investigated for three polymorphisms, all in
the ﬁrst exon of the gene: R52C (C154T), G54D (G161A) and G57E
(G170A). Analysis was performed by PCR and direct sequencing. PCR
was carried out in a total volume of 50 μl containing 100 ng of genomic
DNA, 10 pmol of each primer (forward primer: 5′-GTGAGGATGCCC-
AAAAGACCT-3′; reverse primer: 5′-CATCAGTCTCCTCATATCCCCAG-
3′), 2 mM MgCl2, 200 mM of each dNTP, 10× PCR Buffer and 2 U
AmpliTaqGold DNA polymerase (PE Biosystems Foster City, CA).
Ampliﬁcationswere performed by 35 cycles, each consisting of 30 s
at 96 °C, 30 s at 60 °C and 30 s at 72 °C, using a Gene Amp PCR System
9700 thermal cycler (Perkin-Elmer Biosystems).
Each PCR product was puriﬁed by the PCR Product Pre-Sequencing
Kit (USB Corporation, Ohio), and the DNA sequence analysis was
carried out using the BigDye Terminator Cycle Sequencing Ready-
Reaction kit (Applied Biosystems, UK) and an ABI Prism 3100 DNA
Sequencer (PE Applied Biosystems, Foster City, CA).
Cytokine gene polymorphisms
Single nucleotide variants were analysed in four different cytokine
genes: TNF-α, IF-γ, IL-10 and TG-β1. In particular, the TNF-α gene was
investigated for the transition G to A at position−308 in the promoter
region; the IFN-γ gene was investigated for the T to A polymorphism
at position +874; the IL-10 gene was investigated for three poly-
morphisms in the promoter region: −1082 (G to A), −819 (C to T)and −592 (C to A); the TGF-β1 gene was analysed for two single
nucleotide polymorphisms, both in the coding region, the T29C
(Leu10Pro) and the G74C (Arg25Pro), relative to the translational start
site. These cytokine gene polymorphisms were investigated by the
PCR-SSP methodology, using the One Lambda Cytokine Genotyping
Tray kit (One Lambda, Inc., CA) in accordance with the manufacturer's
instructions.
HFE analysis
Since in Italy the H63D mutation occurs more frequently than the
C282Y mutation (allelic frequencies of 0.1 and 0.01, respectively,
Carella et al., 1997), we restricted our study to the frequency of the
H63D mutation.
Mothers of HCV+ and HCV− childrenwere screened for the H63D
mutation in the second exon of HFE gene. Analysis was performed by
RFLP-PCR as previously described (Pozzato et al., 2001).
Statistical analysis
Allelic frequencies were determined by direct gene counting.
Comparisons were made using the χ2 or Fisher exact test as
appropriate. P valuesb0.05 were considered to indicate statistical
signiﬁcance. Since for all the analysed alleles previous results in adults
have showed an association with HCV infection or liver progression,
no correction of p values was applied.
Data were analysed using free software Open Epi (www.openepi.
com, version 2.2.1), and they are presented as odd ratio and 95%
conﬁdence interval. Conﬁdence intervals were calculated using Fisher
exact formula (Martin and Austin, 1991).
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